表紙
市場調查報告書

非受體型酪胺酸蛋白質激酶TYK2:開發中產品分析

Non Receptor Tyrosine Protein Kinase TYK2 - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 408076
出版日期 內容資訊 英文 100 Pages
訂單完成後即時交付
價格
Back to Top
非受體型酪胺酸蛋白質激酶TYK2:開發中產品分析 Non Receptor Tyrosine Protein Kinase TYK2 - Pipeline Review, H2 2019
出版日期: 2019年12月27日內容資訊: 英文 100 Pages
簡介

本報告提供以非受體型酪胺酸蛋白質激酶TYK2為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您包含最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

非受體型酪胺酸蛋白質激酶TYK2 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Array BioPharma Inc.
  • Bristol-Myers Squibb Company
  • Genentech, Inc.
  • Nimbus Therapeutics, LLC
  • Pfizer Inc.
  • Portola Pharmaceuticals, Inc.
  • Sareum Holdings Plc
  • 武田藥品工業
  • Theravance Biopharma Inc

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC2002TDB

Summary

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) pipeline Target constitutes close to 24 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes. The latest report Non Receptor Tyrosine Protein Kinase TYK2 - Pipeline Review, H2 2019, outlays comprehensive information on the Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Non-receptor tyrosine-protein kinase TYK2 is an enzyme encoded by the TYK2 gene. It is involved in intracellular signal transduction by involving in the initiation of type I IFN signaling. It phosphorylates the interferon-alpha/beta receptor alpha chain. It plays an import role in inflammation. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 5, 2, 12 and 2 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Immunology, Gastrointestinal, Oncology, Musculoskeletal Disorders, Central Nervous System, Dermatology, Respiratory, Metabolic Disorders and Undisclosed which include indications Ulcerative Colitis, Psoriasis, Crohn's Disease (Regional Enteritis), Inflammatory Bowel Disease, Inflammation, Multiple Sclerosis, Plaque Psoriasis (Psoriasis Vulgaris), Rheumatoid Arthritis, Systemic Lupus Erythematosus, T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia), Alopecia Areata, Anaplastic Large Cell Lymphoma (ALCL), Asthma, Atopic Dermatitis (Atopic Eczema), Autoimmune Disorders, Hidradenitis Suppurativa, Psoriatic Arthritis, Vitiligo, Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Ankylosing Spondylitis (Bekhterev's Disease), Arthritis, B-Cell Chronic Lymphocytic Leukemia, B-Cell Non-Hodgkin Lymphoma, Colon Cancer, Colorectal Cancer, Cutaneous T-Cell Lymphoma, Diabetic Macular Edema, Diffuse Large B-Cell Lymphoma, Fibrosis, Follicular Lymphoma, Hypersensitivity, Kidney Cancer (Renal Cell Cancer), Lung Transplant Rejection, Lupus Erythematosus, Lupus Nephritis, Lymphoma, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Pancreatic Cancer, Peripheral T-Cell Lymphomas (PTCL), Skin Cancer, Unspecified and Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma).

Furthermore, this report also reviews key players involved in Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2)
  • The report reviews Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Overview
  • Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Companies Involved in Therapeutics Development
  • AbbVie Inc
  • Amgen Inc
  • Bristol-Myers Squibb Co
  • Merck & Co Inc
  • Nimbus Therapeutics LLC
  • Oncostellae SL
  • Pfizer Inc
  • Portola Pharmaceuticals Inc
  • Sareum Holdings Plc
  • Simcere Pharmaceutical Group
  • Takeda Pharmaceutical Co Ltd
  • Theravance Biopharma Inc
  • Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Drug Profiles
  • ABBV-712 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ARRY-624 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BMS-986165 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • brepocitinib tosylate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • cerdulatinib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NDI-031232 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NDI-031301 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NDI-031407 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • OST-122 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PF-06826647 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SAR-20347 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SART-1 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SDC-1801 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SDC-1802 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Inhibit JAK1, JAK2 and TYK2 for Diabetic Macular Edema - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Inhibit JAK1, JAK2, JAK3 and TYK2 for Asthma - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Inhibit JAK1, JAK2, JAK3 and TYK2 for Rheumatoid Arthritis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Inhibit JAKs for Lung Transplant Rejection - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Inhibit TYK2 for Autoimmune Diseases - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit TYK2 for Inflammation - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit TYK2 for Unspecified Indication - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Synthetic Peptides to Inhibit Tyrosine Kinase 2 for Inflammatory Diseases - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TD-1473 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TD-8236 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Dormant Products
  • Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Discontinued Products
  • Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Product Development Milestones
  • Featured News & Press Releases
  • Dec 09, 2019: Portola Pharmaceuticals presents new interim data at the 61st ASH meeting on its oral SYK/JAK inhibitor Cerdulatinib in heavily pre-treated patients with relapsed/refractory follicular lymphoma
  • Dec 08, 2019: Portola Pharmaceuticals presents new interim data from ongoing phase 2a study of its oral SYK/JAK inhibitor cerdulatinib in heavily pre-treated T-Cell Malignancies
  • Dec 03, 2019: Theravance Biopharma announces dosing of first patient in phase 2 allergen challenge study of TD-8236, an investigational, Lung-selective, inhaled pan-janus kinase (JAK) inhibitor for inflammatory lung diseases
  • Dec 03, 2019: Dermavant announces first patient dosed in phase 2a clinical trial of topical dual JAK/Syk inhibitor Cerdulatinib for Vitiligo
  • Oct 30, 2019: Sareum presents data highlighting the anti-tumour activity of TYK2/JAK1 Inhibitor SDC-1802 in multiple cancer disease models via a novel immunotherapeutic mechanism of action
  • Oct 17, 2019: Sareum Holdings -Research Update -AACR-NCI-EORTC abstract
  • Sep 27, 2019: Sareum TYK2/JAK1 Inhibitor SDC-1802 Demonstrates Anti-tumour Activity in Multiple Cancer Disease Models
  • Sep 09, 2019: Theravance Biopharma reports positive results from phase 1 clinical trial of TD-8236, an investigational, lung-selective, inhaled Pan-Janus Kinase (JAK) inhibitor for inflammatory lung diseases
  • Jun 19, 2019: Portola presents new interim data on its oral SYK/JAK inhibitor cerdulatinib in heavily pre-treated patients with Relapsed/Refractory Follicular Lymphoma
  • May 21, 2019: Theravance Biopharma reports data from phase 1b study of TD-1473 in oral presentation at Digestive Disease Week (DDW) 2019
  • May 14, 2019: Theravance Biopharma announces data from phase 1b study of TD-1473 to be featured in oral presentation at Digestive Disease Week (DDW) 2019
  • Apr 23, 2019: Oncostellae expands partnering activities for OST-122 at the 2019 BIO Int'l Convention in Philadelphia
  • Mar 12, 2019: Theravance Biopharma announces first patient dosed in phase 2b/3 study of TD-1473 in patients with ulcerative colitis
  • Dec 06, 2018: Dermavant Sciences to present new data on Cerdulatinib for atopic dermatitis and vitiligo at the 3rd Annual Inflammatory Skin Disease Summit
  • Dec 03, 2018: Updated interim results from ongoing phase 2a study of Portola Pharmaceuticals' oral Syk/JAK inhibitor Cerdulatinib continues to demonstrate clinical responses in heavily pre-treated T-Cell Malignancies
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indications, H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..3), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..4), H2 2019
  • Number of Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by AbbVie Inc, H2 2019
  • Pipeline by Amgen Inc, H2 2019
  • Pipeline by Bristol-Myers Squibb Co, H2 2019
  • Pipeline by Merck & Co Inc, H2 2019
  • Pipeline by Nimbus Therapeutics LLC, H2 2019
  • Pipeline by Oncostellae SL, H2 2019
  • Pipeline by Pfizer Inc, H2 2019
  • Pipeline by Portola Pharmaceuticals Inc, H2 2019
  • Pipeline by Sareum Holdings Plc, H2 2019
  • Pipeline by Simcere Pharmaceutical Group, H2 2019
  • Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
  • Pipeline by Theravance Biopharma Inc, H2 2019
  • Dormant Projects, H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
Back to Top